Type 1 Diabetes
Conditions
Keywords
Pramlintide,, insulin,, type 1 diabetes,, reduction in postprandial glucose,, pramlintide:insulin dose-ratio
Brief summary
To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
Interventions
OTHERPlacebo
Placebo Comparator
Sponsors
Juvenile Diabetes Research Foundation
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Is 18 to 70 years old * Is male, or is female and meets all the following criteria: 1. Not breastfeeding 2. Negative pregnancy test result and, if of childbearing potential, must practice and be willing to continue to practice appropriate birth control * Has been diagnosed with type 1 diabetes mellitus for at least 1 year and not achieving glycemic goal while on MDI of insulin * Has HbA1c between 7.0% and 9.0% * Has been on MDI of regular insulin, at a dose not to exceed 10 units/breakfast for at least 3 months or has been on continuous subcutaneous insulin infusion (CSII), at a dose not to exceed 10 units/breakfast, for at least 3 months and is willing to switch to an MDI insulin regimen for 1 day prior to enrollment and through the study * Has a body mass index (BMI) \<30 kg/m2
Exclusion criteria
* Has experienced recurrent severe hypoglycemia requiring assistance within 6 months before Visit 1 Screening * Has a history of hypoglycemia unawareness * Has a confirmed diagnosis of gastroparesis * Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications: 1. Any antihyperglycemic agent other than insulin 2. Drugs that directly affect gastrointestinal motility (e.g., anticholinergic agents such as atropine) 3. Drugs that slow the intestinal absorption of nutrients (e.g., α-glucosidase inhibitors. * Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions: 1. Hepatic disease 2. Renal disease 3. Gastrointestinal disease 4. Pulmonary disease 5. Organ transplantation 6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus) * Is currently treated or has been previously treated with SYMLIN/pramlintide or has participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1 (Screening). * Has any clinically significant laboratory findings or medical history that may affect successful completion of the study and/or personal well-being * Has donated blood within 2 months or is planning to donate blood during the study. * Has had a major surgery or a blood transfusion within 2 months * Has received any investigational drug within 1 month * Has known allergies or hypersensitivity to any component of study treatment. * Is an immediate family member of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site. * Is employed by Amylin Pharmaceuticals, Inc (Amylin) (that is an employee, temporary contract worker, or designee responsible for the conduct of the study).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment | AUC 0-3 hrs compared to Placebo |
Secondary
| Measure | Time frame |
|---|---|
| Incremental AUC (0-3 h) of plasma glucagon | 0-3 hrs compared to Placebo |
| Absolute AUC (0-3 h), peak plasma concentration (Cmax), Cave, and Tmax of glucagon of plasma glucose. | 0-3 hrs compared to Placebo |
| PK of pramlintide | 0-3 hrs compared to Placebo |
| Safety | 0-3 hrs compared to Placebo |
Countries
United States
Outcome results
None listed